Effects of sevelamer hydrochloride combined with low calcium dialysate on serum high-density lipoprotein, phosphorus, calcium-phosphate product and adverse reactions in patients undergoing hemodialysis
ZHU Xueli, SU Dongmei, CHEN Zhiyu, and WEN Yue
Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China
Abstract：Objective To investigate the effects of sevelamer hydrochloride combined with low calcium dialysate on high-density lipoprotein, phosphorus, and calcium-phosphorus product of serum and adverse reactions in patients undergoing hemodialysis.Methods Eighty patients with chronic renal failure who underwent hemodialysis in the Department of Nephrology of our hospital between January 2016 and January 2018 were randomly divided into the control group (treated with conventional hemodialysis, n=40) and the experimental group (treated with sevelamer hydrochloride combined with low calcium dialysate, n=40). The course of treatments for both groups was 12 weeks. The changes of lipid metabolism indexes (TC, TG, LDL-C, HDL-C), blood calcium, serum phosphorus, serum calcium-phosphorus product and adverse reactions in both groups were observed.Results There was no significant change in serum calcium concentrations after treatment in the experimental group (P>0.05). The serum calcium concentration (2.75±0.35) mmol/L in the control group was significantly higher after treatment (P<0.05).After treatment, the levels of TC (4.12±0.86) mmol/L, TG (1.21±0.64) mmol/L and LDL-C (2.14±0.38) mmol/L in the experimental group were significantly lower than those in the control group, while HDL-C was significantly higher than that in the control group (P<0.05). The total incidence of adverse reactions was 31.82% in the experimental group, which was significantly higher than 18.18% in the control group (P<0.05).Conclusions Sevelamer hydrochloride combined with low calcium dialysate can significantly improve the levels of serum high-density lipoprotein, serum phosphorus and serum calcium-phosphorus product in patients undergoing hemodialysis, with significant curative effect but without serious adverse reactions.
Lin C J, Pan C F, Chuang C K, et al. Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients.[J]. J Clinic Med Res, 2017, 9(9):765-770.
Habbous S, Przech S, Acedillo R, et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis[J]. Nephrol Dial Transplant, 2017, 32(1):111.
Kim J, Olson K, Butani L. Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease[J]. Pedi Nep, 2016, 31(2):339-341.
2019, Vol. 30 
